Clin2
NCT06999343Possibly a fitNot yet recruiting

Metformin for anti-aging in COPD

COPD

Treatments studied

Part of Lungs & breathing clinical trials.

This study tests if the diabetes drug metformin can slow down aging-related lung decline in people with COPD. You may qualify if you have moderate-to-severe COPD with emphysema and a history of smoking.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
212 people
Ages
40 years to 75 years
Study type
Interventional

Who can take part

  • Be between 40 and 75 years old
  • Have a COPD diagnosis with moderate to severe airflow obstruction
  • Have smoked at least 10 pack-years (e.g., 1 pack a day for 10 years)
  • Have a confirmed decrease in lung function over the last 3 years
  • Have some emphysema seen on a CT scan
  • Not have advanced kidney disease, diabetes, or be on certain other medications

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05466396Recruiting
Study of early COPD lung function in adults

This study looks at lung function in people with early COPD (chronic obstructive pulmonary disease) to understand what happens over time. If you meet the lung test and health requirements, you may be able to help researchers learn how to better track and manage early COPD.

Beijing, Beijing Municipality
NCT07275359Not yet recruiting· Phase 1
Studying a drug to help COPD patients recover from flare-ups

This trial tests if metformin, a diabetes pill, can help older adults with COPD recover better from flare-ups when taken during pulmonary rehabilitation. It focuses on people who have had frequent or severe COPD exacerbations in the last year.

Durham, North Carolina
NCT06459310Recruiting· Phase 2
Testing metformin to slow aging in healthy men

This study tests whether metformin can help slow aging in healthy men. You might be eligible if you are a man in one of two age groups and do not have major health problems.

Beijing
NCT07520110Not yet recruiting· Phase 3
Metformin to slow lung decline in idiopathic pulmonary fibrosis

This study tests whether metformin, a common diabetes medication, can slow the worsening of lung function in people with idiopathic pulmonary fibrosis (IPF)—a serious condition where lung tissue becomes scarred and stiff. Researchers believe metformin may help protect lungs from further damage.

Worcester, Massachusetts
NCT06463743Recruiting· Phase 2
Metformin for aging people with MS

This study tests whether metformin, a common diabetes drug, can help people with multiple sclerosis (MS) as they age. It may be used alone or added to your current MS treatment, and the goal is to see if it slows down aging-related changes in MS.

Buffalo, New York
NCT06273072Recruiting· Phase 2
Metformin for asthma in overweight adults

This trial tests whether the diabetes drug metformin can help people with asthma who are also overweight or obese. The goal is to see if it improves asthma control and reduces the need for rescue medications.

Baltimore, Maryland

Hear when a new COPD trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.